12 June 2023 | News
Fujifilm continues to expand its global footprint to support our customers locally
Fujifilm Corporation will launch a commercial office in Tokyo to provide enhanced sales support and customer service for Contract Development and Manufacturing services for Biologics and Advanced Therapies to Asia-based pharmaceutical and biotechnology companies.
Scheduled to open in July 2023, the new regional commercial office located in Minato, Tokyo, will be part of Fujifilm Diosynth Biotechnologies, a world-leading contract development and manufacturing organisation (CDMO).
Fujifilm Diosynth Biotechnologies provides contract services for process development, small-to-large-scale manufacturing of drug substances and drug products for a variety of therapeutic modalities including monoclonal antibodies, cell and gene therapies, and vaccines.
The global market of biologic-based therapeutics is expected to grow steadily, which is attributed to the increasing demand for monoclonal antibodies and gene therapies. Asia has seen an increasing number of clinical pipelines at a rate of more than 9% in the past 10 years, fueled by strong research and development efforts. This growth trend is expected to continue in the region with an estimated 1,900 new products currently in clinical development.